(19)
(11) EP 4 408 439 A1

(12)

(43) Date of publication:
07.08.2024 Bulletin 2024/32

(21) Application number: 22877643.1

(22) Date of filing: 30.09.2022
(51) International Patent Classification (IPC): 
A61K 31/74(2006.01)
A61K 47/59(2017.01)
 A61K 47/56(2017.01)
A61K 47/69(2017.01)
(52) Cooperative Patent Classification (CPC):
B82Y 5/00; A61K 41/0052; A61K 41/0057; A61K 47/6923; A61K 47/6929; A61K 33/32; A61K 31/12; A61K 33/18
 
C-Sets:
  1. A61K 33/32, A61K 2300/00;
  2. A61K 31/12, A61K 2300/00;
  3. A61K 33/18, A61K 2300/00;
(86) International application number:
PCT/US2022/077427
(87) International publication number:
WO 2023/056470 (06.04.2023 Gazette 2023/14)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 30.09.2021 US 202163250311 P
01.02.2022 US 202263305340 P

(71) Applicants:
  • The Trustees Of Columbia University In The City Of New York
    New York, NY 10027 (US)
  • NewSouth Innovations Pty Limited
    Sydney, NSW 2052 (AU)

(72) Inventors:
  • LEONG, Kam W.
    New York, New York 10032 (US)
  • ZHONG, Yiling
    New York, New York 10032 (US)

(74) Representative: CH Kilger Anwaltspartnerschaft mbB 
Fasanenstraße 29
10719 Berlin
10719 Berlin (DE)

   


(54) MNO NANOMATERIAL BASED INHIBITORS OF INFLAMMATION AND CANCER METASTASIS